In addition, there are data indicating that bone marrow (BM)-MSCs can induce changes in the immune cell phenotypes towards an anti-tumor behavior, such as altering the ratio of Treg and myeloid-derived suppressor cells to CD8+ T cells [117], increasing neutrophil function through Toll-like receptor 3 (TLR3) activation [118, 119], as well as hUCESC inhibiting and reverting macrophage differentiation [27]. Here, TLR3 is linked to neoplasm.